Robin Aglietti

Robin Aglietti serves as the Director of Antibody Discovery at Pythia Labs since October 2024, following a tenure as Head of BioTherapeutics and Principal Scientist at TRexBio from September 2021 to October 2024, where expertise in antibody discovery and engineering was demonstrated. Previously, Robin held the position of Scientist II at Surrozen, focusing on antigen design and label-free technologies. An accomplished Postdoctoral Researcher at Genentech from 2014 to March 2019, significant contributions to understanding Gasdermin D's mechanism of action were made through various advanced techniques and interdisciplinary collaborations. Robinson began an academic journey at the University of California, San Francisco, earning a PhD in Chemistry and Chemical Biology after completing a BS in Biochemistry and Molecular Biology at the University of California, Santa Cruz.